The company had received Four observations in the Form 483
NATCO Pharma Limited receives Establishment Inspection Report (EIR) from US FDA Inspection at our Visakhapatnam, Andhra Pradesh, FDF Unit
The U.S. Food and Drug Administration (FDA) had conducted an inspection at the FDF manufacturing plant located in Parawada, Visakhapatnam, Andhra Pradesh, India, which was conducted from August 17th – August 21st, 2026.
On conclusion of the inspection, the company had received Four observations in the Form 483. We hereby notify that the company has received EIR from the U.S. FDA on the classification as Voluntary Action Indicated (VAI).
Subscribe To Our Newsletter & Stay Updated